Search for: "State v. Lilly"
Results 181 - 200
of 920
Sort by Relevance
|
Sort by Date
1 Dec 2017, 6:20 am
The panel discussion was on the doctrine of equivalents following the Actavis v Lilly decision. [read post]
15 Nov 2017, 8:00 am
” Goodyear v. [read post]
8 Nov 2017, 10:48 pm
THE VOTE - has the decision in Actavis v Eli Lilly improved the law? [read post]
8 Nov 2017, 5:29 am
Part 2 covers claims with numerical limits, relevance of the file history, harmonisation, and a vote as to whether the decision in Actavis v Eli Lilly has improved the law. [read post]
5 Nov 2017, 3:10 pm
Much reliance was placed by Actavis' counsel on the Court of Appeal in Actavis v Merck [2008] EWCA Civ 444 which stated that:“32. [read post]
31 Oct 2017, 12:05 am
Limited and others v Yeda Research and Development Company Limited and others [2017] EWHC 2629 (Pat) - the first application of Actavis v Eli Lilly in the Patents Court. [read post]
17 Oct 2017, 6:09 pm
The panel members were Mattias Zigann, the presiding judge of the Munich Regional Court, Philip Kerr of Allens Linklaters and Larry Welch, the Senior Director, and Assistant General Patent Counsel at Eli Lilly and Company.Mr Ludwig explained that the question of what relief was appropriate had been highlighted by the very recent decision of the United States Court of Appeals for the Federal Circuit in AMGEN INC & ors v. [read post]
16 Oct 2017, 2:57 am
” In its recent judgment of 2 October 2017 (Eli Lilly v. [read post]
6 Oct 2017, 2:34 pm
Eli Lilly, the court reaffirmed that written description is determined based on the state of the art as of a patent’s priority date and that evidence which illuminates the state of the art only subsequent to the priority date is not relevant to written description. [read post]
6 Oct 2017, 2:34 pm
Eli Lilly, the court reaffirmed that written description is determined based on the state of the art as of a patent’s priority date and that evidence which illuminates the state of the art only subsequent to the priority date is not relevant to written description. [read post]
4 Oct 2017, 6:00 am
Nathan Yaffe, Transnational Arbitral Res JudicataSilke Noa Kumpf, Equity-Based Discretion and the Anatomy of Damages Assessment in Investment Treaty LawBoris Kasolowsky, Eric Leikin, Eli Lilly v. [read post]
25 Sep 2017, 7:22 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
25 Sep 2017, 7:22 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
23 Sep 2017, 12:39 pm
Cir. 2015); Eli Lilly, 845 F.3d at 1370. [read post]
18 Aug 2017, 5:56 am
UK Supreme Court moves towards a UK Doctrine of Equivalents in Lilly pemetrexed battle? [read post]
10 Aug 2017, 3:41 pm
UK Supreme Court moves towards a UK Doctrine of Equivalents in Lilly pemetrexed battle? [read post]
8 Aug 2017, 5:06 am
Lilly. [read post]
25 Jul 2017, 1:40 pm
(OFCCP v. [read post]
25 Jul 2017, 5:34 am
UNCT/14/2 Eli Lilly & Co. v Government of Canada, (16 March 2017) ICSID At 10:00 on 17 Aug 2017 I shall give a talk to the IP Summer School at Cambridge entitled Bilateral Investment Treaties & Exporters' Rights Post-Brexit. [read post]
17 Jul 2017, 3:39 pm
Here as promised is the second part of this GuestKat's commentary on Eli Lilly v Actavis UK [2017] UKSC 48, which promises to have much ink spilled and air of various temperatures emitted on its behalf in the coming weeks, months and years. [read post]
